R&D channel feed – Endpoints News

R&D channel feed

A p-value of 0.38? NEJM results raise new questions for Eli Lilly's vaunted Covid antibody

5 years ago

GSK's Hal Barron axes a once-prized drug from J&J, continuing shift away from respiratory

5 years ago

Regeneron posts second look on Covid-19 antibody cocktail, boosting its case for EUA — but what about symptom alleviation?

5 years ago

Gilead hits the brakes on a trifecta of mid- and late-stage studies for their troubled filgotinib program. It's up to the FDA now

5 years ago

Former Allergan program posts positive topline PhIII results in presbyopia in an R&D win post-AbbVie merger

5 years ago

Enhertu picks up another win for AstraZeneca and Daiichi Sankyo, joining the priority review lane for gastric cancer

5 years ago

A dark horse entrant into the spinal muscular atrophy field doubles its value on some PhII data

5 years ago

Bayer follows R&D deal spree by raiding Roche's cancer group for its new research chief

5 years ago

Where's the Pfizer efficacy readout? CEO Bourla says 'soon,' but you're going to have to wait for it

5 years ago

Three years into a PhIII program for a failed Duchenne MD drug, Catabasis hauls down the flag and admits defeat

5 years ago

Ultragenyx slams the brakes on rare disease study after all 5 patients are hit with a serious setback

5 years ago

Crinetics' acromegaly drug hits primary PhII endpoint, but investors can't make up their minds

5 years ago

UPDATE: Forma takes aim at Agios with new AML complete remission data

5 years ago

Novartis succeeds where Alexion failed, coming up with a win for a prized asset in a rare kidney disorder

5 years ago

FibroGen’s new PhIII data set it up for quick OK, analysts say. But can it avoid a black box warning?

5 years ago

What can a biotech entrepreneur and a top scientist come up with on a couple of shared flights? Well...

5 years ago

Mirati plots a march to the FDA for its KRAS G12C drug, breathing down Amgen’s neck with better data

5 years ago

BiondVax stock implodes after a big PhIII gamble for its universal flu vaccine fails

5 years ago

A top drug program at Bayer clears a high bar for CKD — opening the door to an FDA pitch

5 years ago

With lumasiran on the FDA's doorstep, Alnylam reads out new PhIII data in PH1

5 years ago

Years after a major trial setback, Novartis switches gears with SMA drug. This time they're trying it for Huntington's

5 years ago

GlaxoSmithKline's vaccines group aims for a first as it kicks off PhIII RSV studies

5 years ago

Purdue Pharma signs guilty plea, preps $8B+ settlement on Oxy controversy — report; Flagship brings in a comms chief

5 years ago

Biogen spotlights a pair of painful pipeline setbacks as aducanumab showdown looms at the FDA

5 years ago

First page Previous page 184 185 186187188 189 190 Next page Last page